28199983|t|A versatile system for rapid multiplex genome-edited CAR T cell generation
28199983|a|The therapeutic potential of CRISPR system has already been demonstrated in many instances and begun to overlap with the rapidly expanding field of cancer immunotherapy, especially on the production of genetically modified T cell receptor or chimeric antigen receptor (CAR) T cells. Efficient genomic disruption of multiple gene loci to generate universal donor cells, as well as potent effector T cells resistant to multiple inhibitory pathways such as PD-1 and CTLA4 is an attractive strategy for cell therapy. In this study, we accomplished rapid and efficient multiplex genomic editing, and re-directing T cells with antigen specific CAR via a one-shot CRISPR protocol by incorporation of multiple gRNAs in a CAR lentiviral vector. High efficient double knockout of endogenous TCR and HLA class I could be easily achieved to generate allogeneic universal CAR T cells. We also generated Fas - resistant universal CAR T cells by triple gene disruption. Simultaneous gene editing of four gene loci using the one-shot CRISPR protocol to generate allogeneic universal T cells deficient of both PD1 and CTLA-4 was also attempted.
28199983	12	18	system	T169	C0449913
28199983	39	52	genome-edited	T063	C4279981
28199983	53	56	CAR	T116,T129,T192	C4039583
28199983	57	63	T cell	T025	C0039194
28199983	64	74	generation	T052	C3146294
28199983	79	90	therapeutic	T061	C0087111
28199983	91	100	potential	T080	C3245505
28199983	104	110	CRISPR	T114	C3658200
28199983	111	117	system	T169	C0449913
28199983	223	243	cancer immunotherapy	T061	C0278348
28199983	277	297	genetically modified	T063	C4277689
28199983	298	313	T cell receptor	T116,T129,T192	C0034790
28199983	317	342	chimeric antigen receptor	T116,T129,T192	C4039583
28199983	344	347	CAR	T116,T129,T192	C4039583
28199983	349	356	T cells	T025	C0039194
28199983	368	375	genomic	T028	C0017428
28199983	376	386	disruption	T169	C0332453
28199983	399	408	gene loci	T028	C0678933
28199983	421	430	universal	T080	C0175671
28199983	431	442	donor cells	T025	C0007634
28199983	462	478	effector T cells	T025	C3641722
28199983	479	488	resistant	T169	C0332325
28199983	501	511	inhibitory	T052	C3463820
28199983	512	520	pathways	T077	C1705987
28199983	529	533	PD-1	T028	C1418401
28199983	538	543	CTLA4	T028	C1332802
28199983	574	586	cell therapy	T061	C0302189
28199983	596	601	study	T062	C2603343
28199983	649	664	genomic editing	T063	C4279981
28199983	683	690	T cells	T025	C0039194
28199983	696	712	antigen specific	T129	C0456981
28199983	713	716	CAR	T116,T129,T192	C4039583
28199983	732	738	CRISPR	T114	C3658200
28199983	739	747	protocol	T170	C0442711
28199983	777	782	gRNAs	T114,T123	C0082774
28199983	788	791	CAR	T116,T129,T192	C4039583
28199983	792	809	lentiviral vector	T121	C1520007
28199983	833	841	knockout	T063	C0599772
28199983	845	855	endogenous	T169	C0205227
28199983	856	859	TCR	T116,T129,T192	C0034790
28199983	864	875	HLA class I	T109,T129	C0008897
28199983	913	923	allogeneic	T080	C1515895
28199983	924	933	universal	T080	C0175671
28199983	934	937	CAR	T116,T129,T192	C4039583
28199983	938	945	T cells	T025	C0039194
28199983	965	968	Fas	T116,T192	C1454645
28199983	971	980	resistant	T169	C0332325
28199983	981	990	universal	T080	C0175671
28199983	991	994	CAR	T116,T129,T192	C4039583
28199983	995	1002	T cells	T025	C0039194
28199983	1013	1017	gene	T028	C0017337
28199983	1018	1028	disruption	T169	C0332453
28199983	1043	1055	gene editing	T063	C4277689
28199983	1064	1073	gene loci	T028	C0678933
28199983	1093	1099	CRISPR	T114	C3658200
28199983	1100	1108	protocol	T170	C0442711
28199983	1121	1131	allogeneic	T080	C1515895
28199983	1132	1141	universal	T080	C0175671
28199983	1142	1149	T cells	T025	C0039194
28199983	1168	1171	PD1	T028	C1418401
28199983	1176	1182	CTLA-4	T028	C1332802